Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening

Journal of the National Cancer Institute

Volumn 101, Issue 20, 2009, Pages 1412-1422

  Lansdorp Vogelaar, Iris ^a   Van Ballegooijen, Marjolein ^a   Zauber, Ann G ^b   Habbema, J Dik F ^a   Kuipers, Ernst J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GUAIAC;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER MODEL; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; COLONOSCOPY; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; IMMUNOCHEMISTRY; OCCULT BLOOD; PRIORITY JOURNAL; SIGMOIDOSCOPY;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLONOSCOPY; COLORECTAL NEOPLASMS; COST SAVINGS; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; FLUOROURACIL; HUMANS; INCIDENCE; LEUCOVORIN; MALE; MASS SCREENING; MIDDLE AGED; NEOPLASM STAGING; OCCULT BLOOD; ORGANOPLATINUM COMPOUNDS; SEER PROGRAM; SELECTION BIAS; SIGMOIDOSCOPY; SURVIVAL RATE; UNITED STATES;

EID: 70350516341     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djp319     Document Type: Article

References (64)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008 ; 58 ( 2 ): 71-96.
2. Venook A. Critical evaluation of current treatments in metastatic colo-rectal cancer. Oncologist. 2005 ; 10 ( 4 ): 250-261.
3. Schrag D. The price tag on progress-chemotherapy for colorectal cancer. N Engl J Med. 2004 ; 351 ( 4 ): 317-319.
4. Yabroff KR, Mariotto AB, Feuer E, Brown ML. Projections of the costs associated with colorectal cancer care in the United States, 2000-2020. Health Econ. 2008 ; 17 ( 8 ): 947-959.
5. Faivre J, Dancourt V, Lejeune C, et al. Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology. 2004 ; 126 ( 7 ): 1674-1680. (Pubitemid 38736331)
6. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996 ; 348 ( 9040 ): 1472-1477.
7. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996 ; 348 ( 9040 ): 1467-1471.
8. Mandel JS, Bond JH, Church TR, Snover DC, Bradley M, Schuman LM. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med. 1993 ; 328 ( 19 ): 1365-1371.
9. Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst. 1999 ; 91 ( 5 ): 434-437.
10. Atkin WS, Edwards R, Wardle J, et al. Design of a multicentre randomised trial to evaluate fl exible sigmoidoscopy in colorectal cancer screening. J Med Screen. 2001 ; 8 ( 3 ): 137-144.
11. Bretthauer M, Gondal G, Larsen K, et al. Design, organization and management of a controlled population screening study for detection of colorectal neoplasia: attendance rates in the NORCCAP study (Norwegian Colorectal Cancer Prevention). Scand J Gastroenterol. 2002 ; 37 ( 5 ): 568-573.
12. Hoff G, Sauar J, Vatn MH, et al. Polypectomy of adenomas in the prevention of colorectal cancer: 10 years ' follow-up of the Telemark Polyp Study I. Scand J Gastroenterol. 1996 ; 31 ( 10 ): 1006-1010.
13. Prorok PC, Andriole GL, Bresalier RS, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial. Control Clin Trials. 2000 ; 21 ( 6 suppl ): 273S-309S.
14. Segnan N, Senore C, Andreoni B, et al. Baseline fi ndings of the Italian multicenter randomized controlled trial of "once-only sigmoidoscopy"- SCORE. J Natl Cancer Inst. 2002 ; 94 ( 23 ): 1763-1772.
15. Muller AD, Sonnenberg A. Protection by endoscopy against death from colorectal cancer. A case-control study among veterans. Arch Intern Med. 1995 ; 155 ( 16 ): 1741-1748.
16. Newcomb PA, Storer BE, Morimoto LM, Templeton A, Potter JD. Long-term effi cacy of sigmoidoscopy in the reduction of colorectal cancer incidence. J Natl Cancer Inst. 2003 ; 95 ( 8 ): 622-625.
17. Selby JV, Friedman GD, Quesenberry CP Jr, Weiss NS. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med. 1992 ; 326 ( 10 ): 653-657.
18. Pignone M, Saha S, Hoerger T, Mandelblatt J. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2002 ; 137 ( 2 ): 96-104. (Pubitemid 34779153)
19. Warren JL, Yabroff KR, Meekins A, Topor M, Lamont EB, Brown ML. Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst. 2008 ; 100 ( 12 ): 888-897.
20. Sonnenberg A, Delco F, Inadomi JM. Cost-effectiveness of colonoscopy in screening for colorectal cancer. Ann Intern Med. 2000 ; 133 ( 8 ): 573-584. (Pubitemid 30778444)
21. Zauber AG, Lansdorp-Vogelaar I, Wilschut J, Knudsen AB, van Ballegooijen M, Kuntz KM. Cost-effectiveness of DNA Stool Testing to Screen for Colorectal Cancer. Rockville, MD: Agency for Healthcare Research and Quality, 2007. Available at: https://www.cms.hhs.gov/mcd/viewtechassess. asp?where= index&tid=52. Accessed September 11, 2009.
22. National Cancer Institute. Cancer Intervention and Surveillance Modeling Network. (CISNET). Available at: http://cisnet.cancer.gov/. Accessed September 11, 2009.
23. Loeve F, Boer R, van Ballegooijen M, van Oortmarssen GJ, Habbema JDF. Final Report MISCAN-COLON Microsimulation Model for Colorectal Cancer: Report to the National Cancer Institute Project No. NO1-CN55186. Rotterdam, the Netherlands: Department of Public Health, Erasmus University ; 1998.
24. Loeve F, Boer R, van Oortmarssen GJ, van Ballegooijen M, Habbema JDF. The MISCAN-COLON simulation model for the evaluation of colorectal cancer screening. Comput Biomed Res. 1999 ; 32 ( 1 ): 13-33.
25. Loeve F, Brown ML, Boer R, van Ballegooijen M, van Oortmarssen GJ, Habbema JD. Endoscopic colorectal cancer screening: a cost-saving analysis [see comments]. J Natl Cancer Inst. 2000 ; 92 ( 7 ): 557-563.
26. Vogelaar I, van Ballegooijen M, Zauber AG, et al. Model Profi le of the MISCAN-Colon Microsimulation Model for Colorectal Cancer. Rotterdam, the Netherlands: Department of Public Health, Erasmus MC ; 2004.
27. Morson B. President ' s address. The polyp-cancer sequence in the large bowel. Proc R Soc Med. 1974 ; 67 ( 6 ): 451-457.
28. Muto T, Bussey HJ, Morson BC. The evolution of cancer of the colon and rectum. Cancer. 1975 ; 36 ( 6 ): 2251-2270.
29. Arminski TC, McLean DW. Incidence and distribution of adenomatous polyps of the colon and rectum based on 1,000 autopsy examinations. Dis Colon Rectum. 1964 ; 7 ( 4 ): 249-261.
30. Blatt L. Polyps of the colon and rectum: incidence and distribution. Dis Colon Rectum. 1961 ; 4 ( 4 ): 277-282.
31. Bombi JA. Polyps of the colon in Barcelona, Spain. An autopsy study. Cancer. 1988 ; 61 ( 7 ): 1472-1476.
32. Chapman I. Adenomatous polypi of large intestine: incidence and distribution. Ann Surg. 1963 ; 157 ( 2 ): 223-226.
33. Clark JC, Collan Y, Eide TJ, et al. Prevalence of polyps in an autopsy series from areas with varying incidence of large-bowel cancer. Int J Cancer. 1985 ; 36 ( 2 ): 179-186.
34. Jass JR, Young PJ, Robinson EM. Predictors of presence, multiplicity, size and dysplasia of colorectal adenomas. A necropsy study in New Zealand. Gut. 1992 ; 33 ( 11 ): 1508-1514.
35. Johannsen LG, Momsen O, Jacobsen NO. Polyps of the large intestine in Aarhus, Denmark. An autopsy study. Scand J Gastroenterol. 1989 ; 24 ( 7 ): 799-806.
36. Rickert RR, Auerbach O, Garfi nkel L, Hammond EC, Frasca JM. Adenomatous lesions of the large bowel: an autopsy survey. Cancer. 1979 ; 43 ( 5 ): 1847-1857.
37. Vatn MH, Stalsberg H. The prevalence of polyps of the large intestine in Oslo: an autopsy study. Cancer. 1982 ; 49 ( 4 ): 819-825.
38. Williams AR, Balasooriya BA, Day DW. Polyps and cancer of the large bowel: a necropsy study in Liverpool. Gut. 1982 ; 23 ( 10 ): 835-842.
39. Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence-SEER 9 Regs Limited-Use, November 2002 submission (1973-2000).
40. National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2003, based on the November 2002 submission 2003.
41. Loeve F, Boer R, Zauber AG, et al. National Polyp Study data: evidence for regression of adenomas. Int J Cancer. 2004 ; 111 ( 4 ): 633-639.
42. Vogelaar I, van Ballegooijen M, Schrag D, et al. How much can current interventions reduce colorectal cancer mortality in the U.S.? Mortality projections for scenarios of risk-factor modifi cation, screening, and treatment. Cancer. 2006 ; 107 ( 7 ): 1624-1633.
43. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology. 2008 ; 134 ( 5 ): 1570-1595 (Pubitemid 351615355)
44. U.S. Preventive Services Task Force. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008 ; 149 ( 9 ): 627-637.
45. Winawer SJ, Zauber AG, Fletcher RH, et al. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. CA Cancer J Clin. 2006 ; 56 ( 3 ): 143-59 ; quiz 184-185.
46. Levin TR, Zhao W, Conell C, et al. Complications of colonoscopy in an integrated health care delivery system. Ann Intern Med. 2006 ; 145 ( 12 ): 880-886.
47. Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H, Chejfec G. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med. 2000 ; 343 ( 3 ): 162-168.
48. Pox C, Schmiegel W, Classen M. Current status of screening colonoscopy in Europe and in the United States. Endoscopy. 2007 ; 39 ( 2 ): 168-173.
49. Regula J, Rupinski M, Kraszewska E, et al. Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. N Engl J Med. 2006 ; 355 ( 18 ): 1863-1872.
50. Jentschura D, Raute M, Winter J, Henkel T, Kraus M, Manegold BC. Complications in endoscopy of the lower gastrointestinal tract. Therapy and prognosis. Surg Endosc. 1994 ; 8 ( 6 ): 672-676.
51. Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence-SEER 17 Regs Limited-Use, November 2006.
52. submission (1973-2004 varying). National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2007, based on the November 2006 submission ; 2007.
53. Brown ML, Riley GF, Potosky AL, Etzioni RD. Obtaining long-term disease specifi c costs of care: application to Medicare enrollees diagnosed with colorectal cancer. Med Care. 1999 ; 37 ( 12 ): 1249-1259.
54. Yabroff KR, Lamont EB, Mariotto A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst. 2008 ; 100 ( 9 ): 630-641.
55. Bureau of Labor Statistics United States Department of Labor. Consumer Price Index. Washington, D.C 2008. Available at: http://www.bls.gov/cpi/. Accessed September 11, 2009.
56. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fl uorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004 ; 350 ( 23 ): 2343-2351.
57. Kabbinavar FF, Hurwitz HI, Yi J, Sarkar S, Rosen O. Addition of bevaci-zumab to fl uorouracil-based fi rst-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol. 2009 ; 27 ( 2 ): 199-205.
58. de Gramont A, Tournigand C, Andre T, Larsen AK, Louvet C. Adjuvant therapy for stage II and III colorectal cancer. Semin Oncol. 2007 ; 34 ( 2 suppl 1 ): S37-S40.
59. Ladabaum U, Song K, Fendrick AM. Colorectal neoplasia screening with virtual colonoscopy: when, at what cost, and with what national impact? Clin Gastroenterol Hepatol. 2004 ; 2 ( 7 ): 554-563.
60. Tappenden P, Chilcott J, Eggington S, Patnick J, Sakai H, Karnon J. Option appraisal of population-based colorectal cancer screening programmes in England. Gut. 2007 ; 56 ( 5 ): 677-684. (Pubitemid 46662935)
61. Sieg A, Brenner H. Cost-saving analysis of screening colonoscopy in Germany. Z Gastroenterol. 2007 ; 45 ( 9 ): 945-951.
62. Tappenden P, Jones R, Paisley S, Carroll C. The cost-effectiveness of bevacizumab in the fi rst-line treatment of metastatic colorectal cancer in England and Wales. Eur J Cancer. 2007 ; 43 ( 17 ): 2487-2494. (Pubitemid 350086932)
63. Hassan C, Zullo A, Laghi A, et al. Colon cancer prevention in Italy: cost-effectiveness analysis with CT colonography and endoscopy. Dig Liver Dis. 2007 ; 39 ( 3 ): 242-250.
64. Berchi C, Bouvier V, Reaud JM, Launoy G. Cost-effectiveness analysis of two strategies for mass screening for colorectal cancer in France. Health Econ. 2004 ; 13 ( 3 ): 227-238.